BIOMAT Database Logo BIOMAT Database Logo

[Therapeutic response to alpha-interferon in chronic alcoholics with viral hepatitis C]. 1998

I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov

Hepatitis C was treated with interferon alpha in chronic alcoholics and control subjects without alcoholism. The results show that ethanol is an independent risk factor in natural progression of chronic hepatitis C. Moreover, it dose-dependently reduces probability of getting a reliable response to interferon therapy. This makes using interferon alpha treatment of hepatitis C in chronic alcoholics doubtful.

UI MeSH Term Description Entries
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic
D000437 Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) Alcohol Abuse,Alcoholic Intoxication, Chronic,Ethanol Abuse,Alcohol Addiction,Alcohol Dependence,Alcohol Use Disorder,Abuse, Alcohol,Abuse, Ethanol,Addiction, Alcohol,Alcohol Use Disorders,Chronic Alcoholic Intoxication,Dependence, Alcohol,Intoxication, Chronic Alcoholic,Use Disorders, Alcohol
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001706 Biopsy Removal and pathologic examination of specimens from the living body. Biopsies
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D016174 Hepacivirus A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species. Hepatitis C virus,Hepatitis C-Like Viruses,Hepaciviruses,Hepatitis C Like Viruses,Hepatitis C viruses,Hepatitis C-Like Virus
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C.
June 1998, Liver,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Autoantibodies and response to alpha-interferon in patients with chronic viral hepatitis.
November 1990, Journal of hepatology,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
[Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives].
December 1995, Gastroenterologie clinique et biologique,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C.
April 1995, Journal of hepatology,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Clinical and histologic predictors of response to interferon-alpha in patients with chronic hepatitis C viral infection.
December 1994, Digestive diseases and sciences,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients.
January 2010, Journal of Ayub Medical College, Abbottabad : JAMC,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Favorable response to lymphoblastoid interferon-alpha in children with chronic hepatitis C.
February 1998, Journal of hepatology,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
June 1996, Annals of internal medicine,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
[Coinfection with hepatitis G virus in chronic hepatitis C. Response to treatment with interferon alpha].
May 2000, Medicina clinica,
I G Nikitin, and S L Kuznetsov, and O D Liuliaeva, and G I Storozhakov, and V A Kisliakov, and Iu I Uskov
Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha.
September 2012, Transplant international : official journal of the European Society for Organ Transplantation,
Copied contents to your clipboard!